AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Evolus (EOLS) PT Raised to $25 at Stifel Following Settlement
February 19, 2021 1:28 PM ESTStifel analyst Annabel Samimy raised the price target on Evolus (NASDAQ: EOLS) to $25.00 (from $11.00) while maintaining a Buy rating following settlement.
Settlement Is a Win For All; EOLS Shares Released from Overhang... More